Greenwich LifeSciences Inc

NASDAQ:GLSI  
33.44
-0.47 (-1.39%)
Products, Regulatory

Greenwich LifeSciences Presents Five Year Data for GP2 Phase IIb Trial, Showing 0% Recurrence of Breast Cancer

Published: 12/09/2020 14:16 GMT
Greenwich LifeSciences Inc (GLSI) - Greenwich Lifesciences Announces Poster Presentation of Five Year Data for Gp2 Phase Iib Clinical Trial, Showing 0% Recurrence of Breast Cancer.
Greenwich Lifesciences Inc - Kaplan Meier Analysis of Disease Free Survival for Patients Treated With Gp2 Immunotherapy Shows 100% Survival.
Greenwich Lifesciences- Co Now Preparing to Enter Phase Iii Clinical Trial to Treat Similar Population of Moderate to Severe Breast Cancer Patients.